Last reviewed · How we verify
Addition of Hengge Liejing treatment for 48 weeks
Addition of Hengge Liejing treatment for 48 weeks is a Small molecule drug developed by Fujian Medical University Union Hospital. It is currently in Phase 1 development.
At a glance
| Generic name | Addition of Hengge Liejing treatment for 48 weeks |
|---|---|
| Sponsor | Fujian Medical University Union Hospital |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Improvement Effect of Henggliejin on Fatty Liver in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver: (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Addition of Hengge Liejing treatment for 48 weeks CI brief — competitive landscape report
- Addition of Hengge Liejing treatment for 48 weeks updates RSS · CI watch RSS
- Fujian Medical University Union Hospital portfolio CI
Frequently asked questions about Addition of Hengge Liejing treatment for 48 weeks
What is Addition of Hengge Liejing treatment for 48 weeks?
Addition of Hengge Liejing treatment for 48 weeks is a Small molecule drug developed by Fujian Medical University Union Hospital.
Who makes Addition of Hengge Liejing treatment for 48 weeks?
Addition of Hengge Liejing treatment for 48 weeks is developed by Fujian Medical University Union Hospital (see full Fujian Medical University Union Hospital pipeline at /company/fujian-medical-university-union-hospital).
What development phase is Addition of Hengge Liejing treatment for 48 weeks in?
Addition of Hengge Liejing treatment for 48 weeks is in Phase 1.